When to Build vs. Partner vs. Buy: AI Decisions for Pre-Commercial Biotech

Why Pre-Commercial Biotech Is a Different Problem

Most published frameworks for build versus partner versus buy in pharma AI assume an organization with stable revenue, multi-year strategic horizons, and the headcount to staff a strategic in-house team. The framework that PharmExec articulates in “To Build or to Buy” is exemplary of this class: clear, well-structured, and oriented toward organizations with the capacity to make either choice meaningfully.

Pre-commercial biotechs do not have that capacity. The capital constraint is real: even well-funded series B and C biotechs are managing a runway that prioritizes capital deployment toward IND-enabling work, clinical milestones, and platform validation. The team constraint is real: most pre-commercial biotechs operate with fewer than 200 employees, and the science and clinical teams consume most of the headcount. The time constraint is real: AI capability that does not contribute to the next milestone is a distraction the organization cannot afford.

These constraints reshape the build/partner/buy decision in three important ways. First, build is rarely the right answer for capabilities that are not directly tied to the platform’s IP or scientific differentiation. Second, partner is more attractive than it looks, because partnerships convert capability acquisition from a hiring problem into a contracting problem. Third, buy comes with hidden costs — integration, validation, change management — that scale unfavorably for small teams.

The implication is not that pre-commercial biotechs should buy everything; it is that the calculus has to be reframed around what the organization actually needs, on what timeline, with what staff. The standard framework is not wrong; it is calibrated for a different scale of organization.

The Three Paths and What Each Actually Costs

Each path has both visible and hidden costs. Pre-commercial biotechs that evaluate only the visible costs consistently make decisions that look good at the contract signing and disappoint at the eighteen-month mark.

Build. Visible cost: engineering salaries and infrastructure. Hidden cost: the opportunity cost of leadership attention, the multi-year ramp before a built capability matches an off-the-shelf alternative, and the technical debt that accumulates when the organization cannot staff the team at the level required. As IntuitionLabs’ analysis of build versus buy for biotech notes, building in-house offers maximal customization and control over proprietary data and IP, but the prerequisite is sustained executive sponsorship and the ability to attract and retain AI talent — both of which are harder for pre-commercial organizations.

Partner. Visible cost: partnership fees, equity, milestone payments. Hidden cost: shared IP rights, dependency on the partner’s roadmap, and the loss of control that comes with deep integration into another organization’s stack. Partnerships are typically the path that delivers the most capability per dollar in the early years, but they create entanglements that materially shape exit options.

Buy. Visible cost: license fees, implementation, training. Hidden cost: vendor lock-in, integration work to make the tool actually useful in the organization’s workflows, ongoing customization and validation as the science evolves, and the lurking question of what happens when the vendor is acquired or pivots its product roadmap. The compliance dimension matters disproportionately in pharma: European Pharmaceutical Manufacturer’s analysis of compliance-first AI emphasizes that platform evaluation should weight data ownership, interoperability with regulated systems, and the ability to demonstrate compliance — not just feature parity.

The Decision Framework That Works at Sub-Commercial Scale

The decision framework that holds up for pre-commercial biotechs operates on four axes rather than the typical two (cost and time). The four axes are: scientific differentiation, regulatory exposure, capital intensity, and time-to-value.

Scientific differentiation. Does the AI capability contribute to the organization’s scientific edge? If yes, build or partner. If no, buy. Most pre-commercial biotechs have a platform thesis or a therapeutic insight that is the source of their valuation; AI capabilities that support that thesis warrant differentiated investment. AI capabilities that are operational commodities do not.

Regulatory exposure. Will the AI capability touch a regulated workflow that will be inspected? If yes, the validation burden weights heavily against build (because internal validation discipline is harder to staff than vendor-provided validation) and toward buy (where the vendor carries some of the validation work). If no, the calculus is less constrained.

Capital intensity. What is the capital required relative to the milestone the AI capability supports? If the capability requires capital that is large relative to the milestone’s expected value contribution, the decision should default to the lowest-capital option, which is typically buy. If the capability is modest relative to the milestone value, build or partner become more attractive.

Time-to-value. How long until the capability contributes to a milestone? If the answer is less than twelve months, buy. If twelve to thirty-six months, partner. If thirty-six months or longer and the capability is differentiating, build. Pre-commercial biotechs almost never have thirty-six months of patience for a non-differentiating build.

The framework is not algorithmic; it requires judgment about scientific differentiation, regulatory exposure, capital intensity, and time-to-value. But the four axes together produce decisions that hold up better than the two-axis frameworks designed for larger organizations.

Use Case Mapping: Where Build, Partner, and Buy Each Win

Mapping the framework onto typical pre-commercial biotech AI use cases produces recognizable patterns. The mapping is not universal — every biotech’s scientific thesis is different — but the broad strokes hold for most pre-commercial organizations.

Buy is the right default for: regulatory submission drafting tools, pharmacovigilance triage support, clinical trial protocol drafting assistants, document management AI, internal knowledge management, scientific literature search and synthesis, and most commodity productivity tools. These are capabilities where the vendor market has matured, where differentiation is low, and where speed-to-deployment matters more than customization.

Partner is the right default for: platform-specific AI capabilities tied to the biotech’s scientific thesis (target identification, molecular design, biomarker discovery), where a specialist partner brings differentiated science the biotech could not reasonably build in-house. The 2026 wave of platform deals — Eli Lilly with Chai Discovery, GSK with Noetik, Pfizer with Boltz — reflects this pattern at the large-cap end. Pre-commercial biotechs can apply the same logic with smaller partners and tighter scopes, as documented in GEN’s coverage of the 2026 pharma AI platform deals.

Build is the right default for: the narrow set of capabilities directly embedded in the biotech’s scientific or technical IP, where the biotech’s data, the biotech’s domain expertise, and the biotech’s strategic differentiation make external acquisition impossible or counterproductive. The bar should be high: most pre-commercial biotechs that build AI capabilities discover, two years in, that the build was justified by hope rather than by a defensible scientific case.

Milestone Alignment and the Capital Runway Question

Every build/partner/buy decision in a pre-commercial biotech has to be evaluated against the milestone runway. The question is not just “is this AI capability worth the investment?” but “does this AI capability contribute to a milestone within the current runway, and what happens if it does not?”

This reframes the calculus in two ways. First, capabilities that require multi-year development cycles are presumptively wrong for pre-commercial biotechs unless the capability is core to the platform thesis. Second, capabilities that the organization can ramp quickly through buy or partner — even at higher unit cost — often produce better milestone-relevant outcomes than capabilities that require build cycles longer than the milestone window.

The capital runway question is also a vendor risk question. Vendors that depend on a single round of funding, or that have not yet demonstrated commercial traction, introduce a vendor failure risk that is asymmetric for pre-commercial biotechs. The biotech can survive a vendor failure if the AI capability is non-critical; if the capability supports a regulatory submission or a milestone deliverable, vendor failure can be catastrophic. Vendor due diligence for pre-commercial biotechs should include explicit assessment of vendor financial stability, customer concentration, and contingency arrangements.

The dependency runs both ways. As IntuitionLabs’ analysis of the pharma AI vendor landscape indicates, vendor consolidation through M&A is expected to continue in 2026 and beyond. Pre-commercial biotechs that depend on a small vendor should anticipate the possibility that the vendor will be acquired and that the product roadmap will change accordingly.

Vendor Evaluation for the Pre-Commercial Buyer

The vendor evaluation discipline for pre-commercial biotechs has to extend beyond the standard feature-and-price comparison. Five additional dimensions matter disproportionately.

Compliance posture. Pharma compliance is not a feature; it is a precondition. Vendors that cannot articulate their position on 21 CFR Part 11, GDPR, GxP-relevant data handling, and the emerging EMA Annex 22 requirements are not viable for pharma use cases at any scale. Pre-commercial biotechs are particularly vulnerable to vendor compliance gaps because they lack the internal compliance staff to compensate.

Data ownership and portability. What rights does the biotech retain to the data that flows through the vendor’s system? Can the biotech extract its data on contract termination? Can the biotech use its data to train alternative systems? These questions are easy to defer and expensive to resolve later.

Integration with regulated systems. Does the vendor integrate cleanly with the biotech’s MES, LIMS, eTMF, or other regulated systems? Integration is the most consistently underestimated cost of AI deployments in pharma.

Vendor stability and roadmap. What is the vendor’s financial position, customer concentration, and product roadmap? Pre-commercial biotechs should evaluate vendor stability with at least the rigor they apply to clinical CROs and CDMOs.

Validation cooperation. Will the vendor cooperate with validation work, provide validation artifacts, and accept change notification commitments? Vendors that resist these obligations are not viable for GxP-adjacent use cases regardless of feature quality.

Hybrid Patterns That Actually Work

The most successful pre-commercial biotech AI strategies are typically hybrid: buy for commodities, partner for platform capabilities, build for the narrow set of genuinely differentiating capabilities. The hybrid pattern is not an indecision; it is a recognition that different use cases warrant different paths.

Three hybrid patterns recur across pre-commercial biotechs that have made the strategy work.

Buy-then-build. Start by buying a commodity capability, validate the use case, then build a differentiated extension when the scientific case becomes clear. This pattern reduces the risk of premature build and lets the build investment be informed by real operational experience.

Partner-with-IP-protection. Structure platform partnerships with clear IP boundaries that preserve the biotech’s freedom to operate. The partnership delivers near-term capability while protecting long-term optionality. This is harder to negotiate than it sounds and often requires senior leadership engagement.

Buy-with-validation-overlay. Buy commodity AI capabilities, then build the validation, governance, and compliance overlay internally. The build investment is targeted at the discipline that the biotech has to own, while the underlying capability comes from the vendor. This pattern is particularly relevant for GxP use cases where the validation work is the differentiating discipline rather than the AI capability itself.

The common thread across these patterns is that they preserve optionality. Pre-commercial biotechs that lock themselves into multi-year build commitments, or into vendor relationships with no exit path, consistently regret the decisions at the inflection points that define their later stages. The hybrid pattern is not a hedge; it is a deliberate posture that recognizes how much uncertainty exists in the next twenty-four to thirty-six months of any pre-commercial biotech’s life.

The “do nothing” option is usually wrong

One option that pre-commercial biotechs frequently consider is to defer AI investment entirely until the organization is at commercial scale. The logic is appealing: the capital constraint is real, the science teams are busy, the regulatory environment is uncertain, and AI feels like a discretionary investment. The logic is also usually wrong.

Two reasons. First, the AI capabilities that produce the most value at commercial scale require infrastructure, data, and organizational learning that take years to develop. Biotechs that defer AI investment until commercial scale find themselves starting the foundational work at the moment when execution speed matters most. Second, the regulatory environment for AI in pharma is solidifying. Biotechs that wait to start AI work risk facing a more demanding regulatory expectation at the moment they need to deploy, with less time to build the disciplines that the new environment requires.

The right posture is not large-scale AI investment; it is calibrated investment in the AI capabilities that are tractable at pre-commercial scale, with explicit attention to the foundations that the organization will need at commercial scale. The hybrid framework above is designed for exactly this posture: enough investment to build capability and momentum, with optionality preserved for the larger investments that will come later.

How the framework changes at later stages

As pre-commercial biotechs progress through their pipeline — from preclinical to phase 1, phase 2, phase 3, and toward approval — the build/partner/buy framework evolves. Earlier-stage biotechs have less revenue visibility and shorter milestone horizons; later-stage biotechs have more capital, longer planning horizons, and more reason to invest in differentiating capabilities.

The practical implication is that AI decisions made at series B may need to be revisited at series C or D, and again at commercial launch. The hybrid pattern preserves the optionality to revisit; the all-in build or all-in buy commitments often do not. Quality leaders and CIOs at pre-commercial biotechs should make decisions appropriate to the current stage while explicitly designing for the inflection points that will follow. The most expensive AI decisions are those that solve the current stage’s problem perfectly and create constraints that bind the organization at the next stage.

The case for revisiting decisions on a defined cadence

A discipline worth adopting: revisit major AI build/partner/buy decisions on a defined cadence, typically annually, with explicit checkpoint criteria. The criteria might include vendor performance, scientific evolution, regulatory developments, organizational capacity, and competitive landscape. Decisions that no longer pass the criteria should be reopened, even if the cost of switching is real.

This is a difficult discipline because the cost of switching feels high in the moment. But the cost of not switching when the original decision has become obsolete is higher over time, particularly for organizations whose strategic environment is evolving rapidly. The hybrid pattern’s emphasis on preserved optionality is most valuable precisely when the organization is willing to act on it.

References & Sources